Boston Scientific (BSX) investor relations material

Interventional therapies expansion

• Effective Jan. 1, Interventional Therapies will combine interventional cardiology, vascular therapies, interventional oncology and embolization, and, after closing, Penumbra.

• The divisions see R&D overlap in drug delivery and opportunities to leverage products across customer channels, including IVL for coronary and peripheral procedures.

• Growth relies on a broad portfolio and a steady cadence of launches; management said high-single-digit growth, with an aspiration for double digits, is durable beyond 2027.

IVL and coronary drug-coated balloons

• The IVL program uses optical laser technology; management highlighted miniaturization and targeted energy delivery as differentiators, with clinical evidence and registries planned to build the case.

• Early peripheral experience showed fewer balloon exchanges in some procedures; management said treatment may be faster depending on pulse count, while procedure times are already fast.

• Management sees potential for DCBs to reach 30% of PCI, versus 10% of the market currently represented by in-stent restenosis; a large RCT and real-world evidence will support broader use.

• AGENT uses paclitaxel with an excipient designed to retain drug on the balloon; management cited paclitaxel's extensive global DCB use and distinguished balloon delivery from limus-eluting stents.

TCAR and product pipeline

• TCAR faced sales-force disruption, manufacturing transition hiccups and cyber issues; management said the headwinds were nearing resolution and expected a return to double-digit growth.

• Planned 2027 launches include IVUS software with co-registration and a new catheter, plus a more deliverable Wolverine X cutting balloon; another AGENT version is planned on a 12-month cadence.

• Other pipeline items include TCAR enhancements, a full Ranger 035 SFA launch, a single-use TheraSphere option, TruSelect catheter and cryoablation products.